Selling, General, and Administrative Costs: Genmab A/S vs MorphoSys AG

A Tale of Two Biotechs: Genmab A/S vs MorphoSys AG

In the competitive world of biotechnology, managing operational costs is crucial for sustained growth and innovation. Over the past decade, Genmab A/S and MorphoSys AG have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S saw a staggering increase of over 4,000% in SG&A expenses, reflecting its aggressive expansion and investment in research and development. In contrast, MorphoSys AG's expenses grew by approximately 850%, indicating a more conservative approach.

Key Insights

• Genmab A/S: By 2023, their SG&A expenses reached nearly 3.3 billion, showcasing their commitment to scaling operations.
• MorphoSys AG: Despite a peak in 2021, their expenses stabilized around 92 million by 2023, suggesting a strategic focus on efficiency.

This financial narrative highlights the diverse strategies employed by biotech firms in navigating the complexities of the industry.